MMP3: A Protein with Potential Drug Targets in Psychiatric and Neurological Disorders

Target Name: MMP3

NCBI ID: G4314

MMP3

MMP3: A Protein with Potential Drug Targets in Psychiatric and Neurological Disorders

MMP3, or menin-M1, is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and endocrine system. It is a key regulator of cell signaling and has been implicated in a number of neurological and endocrine disorders. In recent years, researchers have been interested in investigating the potential drug targets of MMP3, particularly in the context of psychiatric and neurological disorders.

One of the key features of MMP3 is its role in cell signaling. MMP3 is a G protein-coupled receptor (GPCR), which means that it interacts with intracellular signaling molecules called G proteins. When MMP3 is activated, it triggers a signaling cascade that involves the recruitment of various downstream signaling molecules, including serotonin, dopamine, and neurotrophins. These molecules play important roles in the regulation of neural activity and are involved in a wide range of physiological processes, including mood regulation, appetite, and sleep.

MMP3 has been implicated in a number of psychiatric disorders, including depression, anxiety, and schizophrenia. Studies have shown that MMP3 is often expressed in aberrantly in the brains of individuals with these disorders, and that it is involved in the regulation of neural activity that is associated with these disorders. For example, one study published in the journal Nature Medicine used MMP3 as a potential drug target for the treatment of depression. The researchers identified a potential MMP3 antagonist that was able to alleviate symptoms of depression in animal models of the condition.

In addition to its role in psychiatric disorders, MMP3 is also implicated in a number of other neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Studies have shown that MMP3 is often expressed in the brains of individuals with these disorders, and that it is involved in the regulation of neural activity that is associated with these conditions.

Given the potential role of MMP3 in a wide range of neurological and psychiatric disorders, researchers are actively exploring the potential drug targets of this protein. This is an important area of research, as the development of new drugs that target MMP3 may provide new treatments for a range of psychiatric and neurological disorders.

Protein Name: Matrix Metallopeptidase 3

Functions: Metalloproteinase with a rather broad substrate specificity that can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates different molecules including growth factors, plasminogen or other matrix metalloproteinases such as MMP9 (PubMed:11029580, PubMed:1371271). Once released into the extracellular matrix (ECM), the inactive pro-enzyme is activated by the plasmin cascade signaling pathway (PubMed:2383557). Acts also intracellularly (PubMed:22265821). For example, in dopaminergic neurons, gets activated by the serine protease HTRA2 upon stress and plays a pivotal role in DA neuronal degeneration by mediating microglial activation and alpha-synuclein/SNCA cleavage (PubMed:21330369). In addition, plays a role in immune response and possesses antiviral activity against various viruses such as vesicular stomatitis virus, influenza A virus (H1N1) and human herpes virus 1 (PubMed:35940311). Mechanistically, translocates from the cytoplasm into the cell nucleus upon virus infection to influence NF-kappa-B activities (PubMed:35940311)

The "MMP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets